Kane LP - Search Results

1

Novel Effector Phenotype of Tim-3⁺ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients.

Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL. Liu Z, et al. Among authors: kane lp. Clin Cancer Res. 2018 Sep 15;24(18):4529-4538. doi: 10.1158/1078-0432.CCR-17-1350. Epub 2018 Apr 30. Clin Cancer Res. 2018. PMID: 29712685 Free PMC article.

2

Immune regulation by the TIM gene family.

de Souza AJ, Kane LP. de Souza AJ, et al. Among authors: kane lp. Immunol Res. 2006;36(1-3):147-55. doi: 10.1385/IR:36:1:147. Immunol Res. 2006. PMID: 17337775 Review.

3

TIM-1 and TIM-3 proteins in immune regulation.

Su EW, Lin JY, Kane LP. Su EW, et al. Among authors: kane lp. Cytokine. 2008 Oct;44(1):9-13. doi: 10.1016/j.cyto.2008.06.013. Epub 2008 Aug 15. Cytokine. 2008. PMID: 18706830 Free PMC article. Review.

4

Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion.

Ferris RL, Lu B, Kane LP. Ferris RL, et al. Among authors: kane lp. J Immunol. 2014 Aug 15;193(4):1525-30. doi: 10.4049/jimmunol.1400557. J Immunol. 2014. PMID: 25086175 Free PMC article. Review.

5

PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.

Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane LP, Ferris RL. Li J, et al. Among authors: kane lp. Cancer Res. 2015 Feb 1;75(3):508-518. doi: 10.1158/0008-5472.CAN-14-1215. Epub 2014 Dec 5. Cancer Res. 2015. PMID: 25480946 Free PMC article.

6

Tumor-infiltrating Tim-3⁺ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk.

Li J, Shayan G, Avery L, Jie HB, Gildener-Leapman N, Schmitt N, Lu BF, Kane LP, Ferris RL. Li J, et al. Among authors: kane lp. Oncoimmunology. 2016 Sep 22;5(10):e1200778. doi: 10.1080/2162402X.2016.1200778. eCollection 2016. Oncoimmunology. 2016. PMID: 27853635 Free PMC article.

7

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.

Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Shayan G, et al. Among authors: kane lp. Oncoimmunology. 2016 Dec 23;6(1):e1261779. doi: 10.1080/2162402X.2016.1261779. eCollection 2017. Oncoimmunology. 2016. PMID: 28197389 Free PMC article.

8

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.

Du W, Yang M, Turner A, Xu C, Ferris RL, Huang J, Kane LP, Lu B. Du W, et al. Among authors: kane lp. Int J Mol Sci. 2017 Mar 16;18(3):645. doi: 10.3390/ijms18030645. Int J Mol Sci. 2017. PMID: 28300768 Free PMC article. Review.

9

Increased PD-1⁺ and TIM-3⁺ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.

Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL. Jie HB, et al. Among authors: kane lp. Cancer Immunol Res. 2017 May;5(5):408-416. doi: 10.1158/2326-6066.CIR-16-0333. Epub 2017 Apr 13. Cancer Immunol Res. 2017. PMID: 28408386 Free PMC article. Clinical Trial.

10

Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.

Avery L, Filderman J, Szymczak-Workman AL, Kane LP. Avery L, et al. Among authors: kane lp. Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2455-2460. doi: 10.1073/pnas.1712107115. Epub 2018 Feb 20. Proc Natl Acad Sci U S A. 2018. PMID: 29463725 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114 results

Search Page

Filters